Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 508 clinical trials
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 134 views
  • 14 Dec, 2020
  • 4 locations
None
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

This is a multicenter, multi-cohort, phase 3, double-blinded, placebo-controlled study to assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and TNBC) or tumor BRCA wild type (tBRCAwt) …

adjuvant chemotherapy
HER2
her2/neu-negative breast cancer
hormone therapy
growth factor
  • 0 views
  • 29 Oct, 2021
  • 52 locations
None
Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype. Triple negative breast cancer

  • 2 views
  • 23 Jan, 2021
  • 1 location
None
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.

  • 2 views
  • 17 Nov, 2021
  • 1 location
None
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

capecitabine combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer

  • 0 views
  • 29 Oct, 2021
  • 2 locations
None
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.

  • 0 views
  • 22 Oct, 2021
  • 1 location
None
Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC)

Soluble Tumor Necrosis Factor Receptors (sTNF-Rs) from plasma of patients with advanced, refractory Triple Negative Breast Cancer (TNBC) and for disease control when employed as monotherapy, or in

  • 30 views
  • 27 Jan, 2021
  • 6 locations
None
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal growth factor receptor 2 (HER2) negative/triple-negative breast cancer.

HER2
epidermal growth factor receptor
endocrine therapy
carboplatin
direct bilirubin
  • 0 views
  • 26 Sep, 2021
None
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

This is a multicenter single-arm phase II clinical trial to evaluate the efficacy and safety of olaparib in patients diagnosed of advanced triple negative breast cancer (TNBC) with methylation

ovarian suppression
epidermal growth factor receptor
MRI
BRCA1
progesterone receptor
  • 18 views
  • 29 Jan, 2021
  • 25 locations
None
Study to Evaluate the Safety Tolerability and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

metastatic disease, including an immune checkpoint inhibitor and a single line of platinum containing chemotherapy (for Cohorts B1, B2, C1, and C2) and in adults with metastatic triple-negative breast

  • 0 views
  • 11 Nov, 2021
  • 3 locations